An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
The primary objective of this study was to determine the long-term safety of etanercept in adults with AS who had completed study 0881A3-311-EU.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis|
|Study Start Date:||June 2002|
|Estimated Study Completion Date:||July 2004|
This was an open-label, multicenter extension study that was conducted to evaluate the safety and efficacy of etanercept in the treatment of adult subjects with AS who had completed study 0881A3-311-EU. The study consisted of an open-label treatment period of up to approximately 96 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00421980
|Gent, Belgium, 09000|
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|